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A B S T R A C T
Chikungunya virus (CHIKV) is a mosquito-transmitted virus of special concern as it causes Chikungunya fever,
characterized by an acute febrile illness, rash, and arthralgia that can progress to chronic and debilitating ar-
thritic symptoms. The effects of climate change on the geographic distribution of the mosquito vector has the
potential to expose more of the globe to this virus. No antiviral agents or vaccines are currently available against
CHIKV infection and the development of novel therapies that may lead to a future treatment is therefore ne-
cessary. In this context, the ADP-ribose binding site of the CHIKV nsP3 macro domain has been reported as a
potential target for the development of antivirals. Mutations in the ADP-ribose binding site demonstrated de-
creased viral replication in cell culture and reduced virulence. In this study, 48,750 small molecules were
screened in silico for their ability to bind to the ADP-ribose binding site of the CHIKV nsP3 macro domain. From
this in silico analysis, 12 molecules were selected for in vitro analysis using a CHIKV subgenomic replicon in Huh-
7 cells. Cell viability and CHIKV replication were evaluated and molecules C5 and C13 demonstrated 53 and
66% inhibition of CHIKV replication, respectively. By using a CHIKV-Dual luciferase replicon contain two re-
porter genes, we also demonstrated that the treatment with either compounds are probably interfering in the
early replication rather than after RNA replication has occurred.
1. Introduction
Chikungunya virus (CHIKV) is an arbovirus that belongs to
Alphavirus genus and Togaviridae family (Lumsden, 1955). CHIKV in-
fection can cause fever, skin rash, and arthralgia, and around 15 % of
CHIKV infections can be asymptomatic (Miner et al., 2015). The in-
fection can progress to severe symptoms and persist for months or
years, leading to an economical burden for many countries
(WHO, 2017).
According to the Pan American Health Organization, 349,936 sus-
pected cases were reported in 2016 in the Americas, with 146,914 cases
confirmed by laboratory analysis. No commercial antiviral agent or
vaccine is available against CHIKV infection. Therefore, the develop-
ment of an efficient antiviral agent is need to the treatment of infected
patients.
CHIKV is an enveloped virus with a positive single strand RNA
genome, containing two open reading frames (ORFs). The 5’ ORF en-
codes four non-structural proteins (nsP1 – nsP4) and the 3’ ORF encodes
a subgenomic RNA which encodes the five structural proteins (C, E1,
E2, E3 and 6K) (Kumar et al., 2015; Voss et al., 2010).
Of the CHIKV proteins, nsP3 is the most ‘enigmatic’ since its func-
tions in the virus life cycle remain uncertain (Götte et al., 2018). nsP3
comprises 3 domains: an N-terminal region macro domain, followed by
the alphavirus unique domain (AUD), and the C-terminal hypervariable
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region (Malet et al., 2009; Shin et al., 2012). The nsP3 macro domain is
conserved among alphaviruses and other pathogenic positive single
strand RNA viruses (Eckei et al., 2017). Recently, the ADP-ribosylhy-
drolase activity of CHIKV nsP3 macro domain was shown to be critical
for virus replication and virulence (McPherson et al., 2017).
Previously, the macro domain of CHIKV nsP3 has been described as
a potential target in the development of anti-alphavirus compounds
(Nguyen et al., 2014; Subudhi et al., 2018; Vijayasri and Hopper, 2017).
Despite the interest in the macro domain of nsP3, there is a lack of in
vitro or in vivo studies on drugs that bind to this region of nsP3. Most are
computational studies, with no further in vitro or in vivo validation
(Nguyen et al., 2014; Vijayasri and Hopper, 2017). Computational
methods can be useful to refine the search for new antiviral drugs, re-
ducing efforts and costs to approve antivirals, however, the validation
of these analysis is essential.
In this study, we combined a virtual screening cascade to identify
small molecules that putatively bind to ADP-ribose site of the macro
domain of nsP3 and further investigated the antiviral activity of the
selected molecules in vitro.
2. Material and Methods
2.1. In silico screening
An in-house library containing small synthetic molecules from the
Medicinal Chemistry/Chemical Biology (MCCB) group (School of
Chemistry, Faculty of Engineering & Physical Sciences - University of
Leeds) was docked to the ADP-ribose binding site of the CHIKV nsP3
macro domain (Protein Data Bank - 3GPO) (Malet et al., 2009) using the
docking algorithm Glide (vHTS mode). Molecules were ranked ac-
cording to predicted binding affinity and the top compounds were re-
docked using Glide XP mode (Maestro, Schrödinger, LLC, New York,
NY, 2017). Then the compounds were visually inspected. Based on
these parameters, 12 compounds were selected for in vitro activity as-
says.
2.2. Compounds
The 12 compounds selected by in silico screening were kindly pro-
vided by MCCB group. Compounds were stored at 14°C in 10 mM
DMSO stock solutions, in 0% humidity cabinets. After initial in vitro
assays, new stocks of compounds C5 (ChemDiv V029-0567), C13
(ChemDiv V028-7674) and their respective analogs were purchased
(ChemDiv inc, San Diego - US).
2.3. Cell lines and replicons
The human hepatoma (Huh-7) and rhabdomyosarcoma (RD) cell
lines were grown in DMEM, supplemented with 10% FBS, 0.5 mM non-
essential amino acids and 100 units/mL penicillin-streptomycin.
Murine myoblast cells (C2C12) were grown in DMEM supplemented
with 20% FBS and 100 units/mL penicillin-streptomycin. All cells were
maintained at 37°C with 5% CO2 in a humidified incubator.
The subgenomic replicons CHIKV wild type nsP3 firefly luciferase
(CHIKV-Fluc SGR) and CHIKV dual luciferase (CHIKV-D-Luc SGR) were
derived from the ECSA genotype LR2006-OPY1 (Pohjala et al., 2011).
2.4. Cell viability assay
Cell viability was measured by MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide] (Sigma–Aldrich) assay. 24 hours
post treatment, compound-containing media was removed from 96 well
plates and MTT at 1 mg/mL solution was added to each well, incubated
for 1 hour and replaced with 100 μL of DMSO to solubilize the formazan
crystals. The absorbance was measured at 560 nm on Infinite F50 mi-
croplate reader (Tecan). Cell viability was calculated according to the
equation (T/C) × 100%, which T and C represented the optical density
of the treated well and control groups, respectively. DMSO was used as
non-treated control. The cytotoxic concentration of 50% (CC50) was
calculated using Prism (Graph Pad).
2.5. RNA Transcription and electroporation
Plasmids were linearized using restriction enzyme NotI-HF (New
England Biolabs), prior to in vitro transcription using the mMESSAGE
mMACHINE™ SP6 Transcription Kit (Invitrogen) following the manu-
facturer's protocol. RNA was purified using the LiCl precipitation pro-
tocol. For electroporation, 3×106 cells were electroporated with 2 µg of
RNA in 4 mm cuvette, 260 V, 25 ms, 1 pulse, using GenePulser Xcell
(Bio-Rad) (Roberts et al., 2017). Cells were plated in 48 well plates
(6 × 104 cells/well) for replication assays and 96 well plates (2 × 104
cells/well) for cell viability assays. Four hours post-electroporation
(h.p.e.) the media was removed, replaced with compound-containing
media in different concentrations and incubated for 24 hours.
2.6. Replication assay
To measure CHIKV replication levels, compound-containing media
was removed 24 hours after treatment, cells were washed with PBS, and
harvested by lysis with Passive Lysis Buffer (Promega). Samples were
stored at − 20°C and thawed prior to measurement of luminescence
levels on a FLUOStar optima microplate reader (BMG Labtech) using
the Luciferase Assay System (Promega) for CHIKV-Fluc SGR and the
Dual-Luciferase® Reporter system (DLR™) (Promega) for CHIKV-D-Luc
SGR. The effective concentration of 50% (EC50) was calculated using
Prism (Graph Pad). Replication assays were carried out in parallel with
cell viability assays.
2.7. Statistical Analysis
Individual experiments were performed in triplicate and all assays
were performed a minimum of three times in order to confirm the re-
producibility of the results. Statistical analysis was performed using
GraphPad Prism software. A Kruskal-Wallis test followed by post hoc
analysis by Dunn's test was used for multiple comparisons
P values of less than 0.05 (indicated by asterisks) were considered
statistically significant.
3. Results
3.1. In silico identification of ligands to the Macro domain of CHIKV-nsP3
To identify potential inhibitors against the macro domain of CHIKV
nsP3, the structure of CHIKV nsP3 complexed with ADP-ribose (Protein
Data Bank - 3GPO) was used. The ADP-ribose substrate was manually
removed from the ADP-ribose binding site and a library containing
48,750 small synthetic molecules were docked to this region of the
protein with Schrodinger's docking tool Glide in vHTS mode using de-
fault parameters. The compounds were ranked based on Glide docking
scores, a prediction of binding affinity, and the top 1000 scoring
compounds were re-docked using Glide XP mode, a higher precision
scoring function. After that, the top 50 compounds were visually in-
spected. And 12 compounds were selected for biological testing based
on the docking score (Table 1); inspection of hydrogen bonds between
ADP-ribose binding site of CHIKV nsP3 and the compounds; the con-
formation of each docking pose and the position of the compound in-
side the binding site relative to the ADP-ribose.
3.2. Activity of compounds against CHIKV replication
3.2.1. Initial in vitro activity of compounds selected by docking analysis
The 12 compounds selected by docking analysis were evaluated in
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vitro by their antiviral activity using the CHIKV-Fluc SGR system. Huh-7
cells were electroporated with CHIKV-Fluc SGR RNA, seed in 48 well
plates and treated with each compound at 20 μM, 10 μM and 1 μM at 4
h.p.e. to assess the effect of these compounds on both CHIKV replication
and cell viability. Figure 1 presents data obtained from the treatment
with the maximum non-toxic concentration of each compound. The
results demonstrated that at 20 μM compounds C5 and C13 inhibited
CHIKV replication by 53% and 66% respectively, and retained 94% of
cell viability (Figure 1, Table 1). Other compounds did not demon-
strate significant activity against CHIKV replication.
3.2.2. Compounds with anti-CHIKV activity and related analogues
In silico analysis showed predicted hydrogen bonding interactions of
compounds C5 and C13 with residue Tyr114 and van der Waals inter-
actions/hydrophobic effect with residue Val33 and Asn24 (Figure 2A).
After initial in vitro screening, compounds C5 and C13 were selected for
further assays and structural analogues were purchased from ChemDiv
(Figure 2B).
The EC50 and CC50 of C5, C13 and their analogues were determined
by performing replication and viability assays in cells treated with a
range of concentrations of each compound. Huh-7 cells were
electroporated with CHIKV-Fluc SGR RNA, seeded in 48 well plates and
treated with a two-fold dilution (ranging from 1.5-100 μM) of each
compound at 4 h.p.e. Cell viability and CHIKV replication levels were
measured 24 h post treatment (Figure 3). The selective index (SI) was
calculated by dividing the value of CC50 by EC50 (CC50/EC50). The EC50
and CC50 values and SI of C5, C13 and their analogues are shown in
Table 2. Compound C5 showed EC50 of 12.7 μM and CC50 of 38.9 μM,
and demonstrated lower EC50 value than its analogues 1C5, 2C5, 3C5
and 4C5. Compound C13 presented a slightly higher EC50 (11.9 μM)
and CC50 (36.8 μM). While the C13 analogue 1C13 showed a decrease
in EC50, the value o6 CC50 decreased almost by a half.
3.2.3. Investigation of C5 and C13 compounds mechanisms
Compounds C5 and C13 presented the highest SI and their effects on
CHIKV replication were further investigated. To this end, the CHIKV-D-
Luc replicon containing two reporter genes, the renilla luciferase (Rluc)
and firefly luciferase (Fluc) was used, the replicon is described in
(Roberts et al., 2017). The reporter Rluc is present in the hy-
pervariable region of nsP3 of CHIKV and its expression indicate both
input translation and early replication levels. Alternatively, the reporter
Fluc replaces the virus structural genes and it is only expressed from a
Table 1
Docking scores, physicochemical properties and biological activity of selected ligands docked to ADP-ribose binding site at the macro domain of CHIKV nsP3.















HBA HBD MW PSA
C9 1 None None 7 -10,778 1,152 4 2 359,352 91,65
C3 3 None None 12 -10,371 3,453 5 3 476,548 133,73
C14 8 None None 12 -9,695 4,193 3 2 484,03 78,51
C1 14 None None 6 -9,435 1,64 5 1 344,388 114,35
C13 16 66% None None 11 -9,388 2,73 4,81 5 1 470,444 84,4
C4 21 None None 12 -9,153 1,751 6 2 499,531 106,2
C5 30 53% None None 11 -8,972 3,025 4 1 466,548 70,84
C17 33 None None 6 -8,952 1,723 4 2 407,871 117,95
C12 46 None None 3 -8,751 3,324 2 0 368,857 40,62
C8 48 None None 9 -8,735 4,065 3 1 413,512 56,15
C16 50 None None 6 -8,7 1,403 3 2 368,43 81,75
Figure 1. In vitro screening of 12 MCCB com-
pounds selected from docking analyses.
CHIKV-Fluc SGR replicon scheme (A).
Schematic representation of in vitro initial
trials of MCCB compounds (B). The results of
the treatment with maximum non-toxic con-
centration of Huh-7 cells harbouring CHIKV-
Fluc SGR are shown for cell viability and ac-
tivity against CHIKV replication (C). DMSO
was used as non-treated control. The asterisks
indicate statistically significant differences be-
tween each compound and DMSO control (*p
≤ 0.05, **p ≤ 0.01), calculated using the
Kruskal–Wallis test with the Dunn's post test.
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subgenomic RNA, thus indicating that RNA replication has occurred
(Figure 4A). In order to investigate a possible mechanism of C5 and
C13 were acting during early or late replication, Huh-7 cells were
electroporated with CHIKV-D-Luc and treated with C5 (Figure 4B) or
C13 (Figure 4C) at non-toxic concentrations (concentrations above
80% of cell viability were considerated non-toxic). The data obtained
demonstrated that the treatment with C5 (Figure 4B) and C13
(Figure 4C) compound significantly decreased Rluc levels, but not Fluc
. Therefore, suggesting that these compounds are most likely interfering
Figure 2. Structure of compounds C5, C13 and analogues. (A) Predicted binding conformations of C5 and C13 docked within to the ADP-ribose binding site of CHIKV
nsP3 macro domain. Predicted hydrogen bonding interactions between 2D compound structures and CHIKV nsP3 amino acids are shown with a dotted line. (B)
Molecular structures of the selected analogues (1C5, 2C5, 3C5, 4C5).
Figure 3. Activity of selected compounds and analogues against CHIKV replication. Huh-7 cells were electroporated with CHIKV-Fluc-SGR RNA, seed and treated 4 h
later with compounds at concentrations ranging from 100µM to 3µM. Cell viability (■) was measured by MTT and replication (●) by luciferase assay 24 h post
treatment. DMSO was used as non-treated control. P < 0.05 was considered significant, the asterisks indicate statistically significant differences between each
compound and DMSO control (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001), calculated using the Kruskal–Wallis test with the Dunn's post test.
Table 2
EC50 and CC50 of C5 and C13 analogues.
Compound EC50 (µM) CC50 (µM) SI
C5 12.7 38.9 3.1
1C5 19.8 27.5 1.4
2C5 27.3 27.4 1.0
3C5 26.9 40.5 1.5
4C5 29.3 45.2 1.5
C13 11.6 36.8 3.2
1C13 6.9 18.1 2.6
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with early replication events.
Finally, the effects of C5 and C13 were also investigated in muscle
derived cell lines. For this, human rhabdomyosarcoma (RD) cells and
murine myoblast (C2C12) cells were used. However, the results de-
monstrated that C5 and C13 were only able to inhibit CHIKV replication
at concentrations that also demonstrated some cell toxicity (Figure 5).
At 100 µM, C5 inhibited 100% and 70% of CHIKV replication in RD and
C2C12, respectively (cell viability 65% and 49%) (Figure 5A and 5B).
C13 inhibited CHIKV replication in 95% and 64% in RD and C2C12,
respectively (cell viability 70% and 51%) (Figure 5B and 5D).
Figure 4. Effect of C13 and C5 at different stages in CHIKV replication. CHIKV-D-Luc wild type RNA (A) were electroporated in Huh-7 cells used to analyse the
activity of C5 (B) and C13 (C). DMSO was used as non-treated control. The asterisks indicate statistically significant differences between each compound and DMSO
control (*p ≤ 0.05, **p ≤ 0.01). P < 0.05 was considered significant calculated using the Kruskal–Wallis test with the Dunn's post test.
Figure 5. Activity of C5 and C13 in RD and C2C12 cell lines. Cells were electroporated with CHIKV-Fluc RNA, seeded and after 4h treated with C5 or C13. Cell
viability and replication were measured in RD (A and B) and C2C12 cells (C and D). DMSO was used as non-treated control. The asterisks indicate statistically
significant differences between each compound and DMSO control, cell viability differences (grey asterisks) and replication differences (black asterisks). P < 0.05
was considered significant (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001), calculated using the Kruskal–Wallis test with the Dunn's post test.
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4. Discussion
Virtual screening has the advantage of reducing costs/time to
identify hit compounds when compared to screening large numbers of
compounds in an HTS approach (Piccirillo and Amaral, 2018). In this
study, the macro domain of CHIKV nsP3 was investigated since this
protein has been reviewed and described to participate in several pro-
cesses of the viral cycle.
The macro domain of CHIKV nsP3 possesses ADP-ribose binding and
ADP-ribose hydrolase activity, removing ADP-ribose from mono(ADP-
ribosyl)ated proteins, this activity has been shown to be important for
viral replication (McPherson et al., 2017). CHIKV mutants with reduced
hydrolase activity showed slower virus replication and decrease of
virulence, and mutants with no hydrolase activity were unable to re-
plicate in mammalian or mosquito cells (McPherson et al., 2017).
Therefore, a compound that can block CHIKV nsP3 hydrolase activity is
proposed to be a target for antiviral therapy. Additionally, the macro
domain of nsP3 is a well conserved region in the Alphavirus genus and
other positive single strand RNA viruses, demonstrating the potential to
be a broad spectrum antiviral (Eckei et al., 2017; Gregor et al., 2016).
A library of 48,750 small molecules was initially screened in silico to
predict their ability to bind to ADP-ribose binding site of nsP3. Twelve
selected compounds were further investigated in vitro for both their
toxicity to human hepatoma cells and antiviral activity on CHIKV re-
plication. Compounds C5 and C13 presented the highest selective index
(ratio between the cell viability and the replication inhibition) (5.2 and
31, respectively), and demonstrated to share a similar mode of binding
to ADP-ribose binding site, in terms of shape and electrostatic potential.
Therefore, analogues of C5 and C13 were also investigated, however,
they were less active than the original compounds. Moreover, C5 and
C13 demonstrated interference in the early steps of CHIKV replication
(for example formation of the replication complex) rather than after
RNA replication has occurred.
However, most of the computer-aided virtual screening studies
based on CHIKV nsP3 describe only in silico data (Pérez-Pérez et al.,
2019). Nguyen and collaborators used the database Diversity Set II
chemical library of the National Cancer Institute (NCI) to virtually
screen 1541 compounds in conjunction with the structure of the CHIKV
nsP3 macro domain from the Protein Data Bank (PDB id: 3GPG) and
selected five potential ligands (Nguyen et al., 2014). Vijayasri and
collaborators also used the same CHIKV nsP3 macro domain structure
to dock 150 phytochemicals from various plant sources, among them
fisetin and quercetin (Vijayasri and Hopper, 2017). Later, the phyto-
chemical fisetin and quercetagetin, compound similar to quercetin,
showed in vitro anti-CHIKV activity by inhibiting RNA production and
viral protein expression (Lani et al., 2016). Baicalein was also con-
sidered a potential antiviral candidate against CHIKV nsP3 in a com-
putational study (Seyedi et al., 2016). In 2018, Oo and collaborators
showed that baicalein also exhibited binding affinity to CHIKV en-
velope protein E2. Baicalein present higher inhibition on virus entry
than replication. The authors suggested a possible interaction between
the compound and cellular factors (Oo et al., 2018).
ADP-ribosylation is a common post-translational modification in
cellular proteins (Hottiger et al., 2010). In this regard, the tested
compounds showed considerable cytotoxicity, this might be because
they were selected to bind to the ADP-ribose binding site of nsP3. By
definition this will be similar to the ADP-ribose binding site of cellular
macrodomains (Schleicher et al., 2018). ADP-ribosylation is known to
regulate cell DNA repair, cell proliferation, transcription and cell death
(Barkauskaite et al., 2015; Munnur and Ahel, 2017). Therefore, we
suggest that these selected compounds against nsP3 macrodomain may
be acting on these other cell pathways affecting cell viability.
In this regard it is interesting to note that compounds C5 and C13
showed higher cytotoxicity in muscle derived cell lines RD and C2C12.
Roberts and collaborators, showed that different cell lines present
variance in the levels of replication (Roberts et al., 2017). The
cytotoxicity observed for RD and C2C12 cell lines could be related to
the metabolism of these cells, as well as their ability to support CHIKV
replication.
In addition interferon treatment induces the expression of several
cellular ADP-ribosyltransferases which act as inhibitors of cellular
translation and virus replication (Atasheva et al., 2014), leading to the
hypothesis that de-ADP-ribosylation activity of macro domains can act
as a response to cellular antiviral mechanisms. Inhibition of nsP3 macro
domain activity would therefore have a two-pronged effect – direct
inhibition of viral RNA replication and potential blockade of the innate
immune response. However, more studies are needed to precisely un-
derstand the role(s) of the nsP3 macro domain during the virus life-
cycle.
5. Conclusion
In this study a virtual screening approach has been used to identify
putative CHIKV nsP3 inhibitors that target the ADP-ribose binding site.
In vitro analysis showed that two of the selected compounds inhibited
CHIKV replication, probably acting in the early replication. Computer-
aided drug design (CADD) is a facilitator in the process of searching for
new antivirals, however, the selection of compounds by docking does
not eliminate other variables in a living system and needs to be com-
bined with biological assays.
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